The World Health Organization (WHO) announced on Monday that it has approved the Bavarian Nordic mpox vaccine, known as Jynneos, for adolescents aged 12 to 17 years. This significant decision aims to protect a particularly vulnerable age group from mpox, a viral infection that has raised global health concerns in recent years.

On October 8, the WHO granted prequalification for the Jynneos vaccine for adolescents, highlighting its commitment to safeguarding public health. This move follows the organization’s declaration of mpox as a global public health emergency for the second time in two years. The recent outbreak began in the Democratic Republic of Congo and quickly spread to neighboring countries, prompting increased vigilance.

Mpox, which can cause flu-like symptoms and skin lesions filled with pus, poses a higher risk to children, adolescents, and individuals with weakened immune systems. The WHO previously approved the Jynneos vaccine for adults in September, making it more accessible for countries in Africa that have been severely affected by mpox. This earlier approval was a crucial step in the fight against the disease, enabling adults in high-risk regions to receive protection.

The latest decision from the WHO aligns with the European Union's approval of the vaccine for adolescents in September, marking a coordinated global response to the ongoing threat of mpox. By extending the vaccine's use to younger populations, health officials hope to mitigate the impact of the disease and reduce the potential for future outbreaks.

As the WHO continues to monitor the situation, the approval of the mpox vaccine for adolescents represents a significant advancement in public health efforts. This proactive measure not only aims to protect young individuals but also reinforces the importance of vaccination in controlling infectious diseases.

With the introduction of the Jynneos vaccine, there is hope for better protection against mpox, particularly in regions where the virus has been prevalent. As health authorities prepare for widespread vaccination efforts, the focus remains on ensuring that the most vulnerable populations receive timely access to this crucial vaccine.

WHO Approves First Diagnostic Test for Mpox to Combat Rising Cases

India's Vaccine Regulatory System Meets WHO Standards for Safety and Quality